Phillip Parente
Overview
Explore the profile of Phillip Parente including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
61
Citations
832
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Dennett A, Harding K, Peiris C, Shields N, Barton C, Lynch L, et al.
JMIR Res Protoc
. 2022 Jul;
11(7):e38553.
PMID: 35849441
Background: Access to rehabilitation to support cancer survivors to exercise is poor. Group exercise-based rehabilitation may be delivered remotely, but no trials have currently evaluated their efficacy. Objective: We aimed...
12.
Anton A, Pillai S, Semira M, Wong S, Shapiro J, Weickhardt A, et al.
BJUI Compass
. 2022 May;
3(3):205-213.
PMID: 35492221
Introduction: Several systemic therapies have demonstrated a survival advantage in metastatic castration resistant prostate cancer (mCRPC). Access to these medications varies significantly worldwide. In Australia until recently, patients must have...
13.
Chazan G, Anton A, Wong S, Shapiro J, Weickhardt A, Azad A, et al.
Asia Pac J Clin Oncol
. 2022 Jan;
18(6):642-649.
PMID: 35098653
Aims: Multiple life-prolonging therapies are available for metastatic castration-resistant prostate cancer (mCRPC). However, the optimal treatment strategy following progression through standard treatment with docetaxel, androgen receptor signaling inhibitor (ARSI) and...
14.
Dennett A, Harding K, Reimert J, Morris R, Parente P, Taylor N
JMIR Cancer
. 2021 Dec;
7(4):e33130.
PMID: 34854817
Background: Access to exercise for cancer survivors is poor despite global recognition of its benefits. Telerehabilitation may overcome barriers to exercise for cancer survivors but is not routinely offered. Objective:...
15.
Kelly R, Anton A, Wong S, Shapiro J, Weickhardt A, Azad A, et al.
BJU Int
. 2021 Oct;
128 Suppl 1:18-26.
PMID: 34622543
Objectives: To investigate the recent real-world use of first-generation antiandrogens (FGAs) in metastatic castration-resistant prostate cancer (mCRPC) using a retrospective multicentre cohort study. Patients And Methods: The electronic CRPC Australian...
16.
Kwan E, Spain L, Anton A, Gan C, Garrett L, Chang D, et al.
Eur Urol
. 2021 Sep;
81(3):253-262.
PMID: 34493414
Background: Immune checkpoint inhibitor monotherapy in metastatic castration-resistant prostate cancer (mCRPC) has produced modest results. High-dose radiotherapy may be synergistic with checkpoint inhibitors. Objective: To evaluate the efficacy and safety...
17.
Anton A, Wong S, Shapiro J, Weickhardt A, Azad A, Kwan E, et al.
Eur J Cancer
. 2021 Aug;
157:485-492.
PMID: 34344533
Introduction: Bone metastases occur frequently in castration-resistant prostate cancer (CRPC) and may lead to skeletal-related events (SREs), including symptomatic skeletal events (SSEs). Bone-modifying agents (BMAs) delay SREs and SSEs. However,...
18.
Cmero M, Kurganovs N, Stuchbery R, McCoy P, Grima C, Ngyuen A, et al.
JCO Precis Oncol
. 2021 Jul;
5.
PMID: 34322653
Purpose: Androgen receptor (AR) signaling is important in prostate cancer progression, and therapies that target this pathway have been the mainstay of treatment for advanced disease for over 70 years....
19.
Fettke H, Kwan E, Bukczynska P, Steen J, Docanto M, Ng N, et al.
Prostate
. 2021 Jul;
81(13):992-1001.
PMID: 34254334
Background: The androgen receptor (AR) pathway-associated gene nuclear receptor coactivator 2 (NCOA2) has an established oncogenic role in early prostate cancer and likewise is a driver of metastatic disease and...
20.
Kwan E, Fettke H, Crumbaker M, Docanto M, To S, Bukczynska P, et al.
Transl Androl Urol
. 2021 May;
10(4):1688-1699.
PMID: 33968657
Background: As potent systemic therapies transition earlier in the prostate cancer disease course, molecular biomarkers are needed to guide optimal treatment selection for metastatic hormone-sensitive prostate cancer (mHSPC). The value...